Trial Profile

A Rollover Study to Provide Continued Treatment With M6620 (ATRi Transition Rollover Study)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Berzosertib (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Merck KGaA

Most Recent Events

28 Nov 2024 Protocol was amended to include only Berzosertib as monotherapy and arm with carboplatin and paclitaxel has been removed, hence changes in the treatments and in the primary endpoints observed.
28 Nov 2024 Status changed from active, no longer recruiting to completed.
15 Nov 2023 Planned End Date changed from 11 Oct 2023 to 15 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com